Therapeutic Antioxidant Medical Gas

Atsunori Nakao¹,²,³*, Ryujiro Sugimoto²,³, Timothy R Billiar³, and Kenneth R McCurry²,³

¹Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
²Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
³Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA

Received 24 July, 2008; Accepted 5 August, 2008

Summary Medical gases are pharmaceutical gaseous molecules which offer solutions to medical needs and include traditional gases, such as oxygen and nitrous oxide, as well as gases with recently discovered roles as biological messenger molecules, such as carbon monoxide, nitric oxide and hydrogen sulphide. Medical gas therapy is a relatively unexplored field of medicine; however, a recent increasing in the number of publications on medical gas therapies clearly indicate that there are significant opportunities for use of gases as therapeutic tools for a variety of disease conditions. In this article, we review the recent advances in research on medical gases with antioxidant properties and discuss their clinical applications and therapeutic properties.

Key Words: medical gas, antioxidant, carbon monoxide, hydrogen, nitric oxide

Introduction

The use of medical gases to treat oxidative stress is an exciting and evolving therapeutic possibility. Oxidative stress is the process of cellular injury caused by excessive levels of reactive oxygen species (ROS). ROS are highly reactive, unstable molecules generated during a variety of energy-generating biochemical reactions and cellular functions. ROS function as necessary signaling molecules, critically modulate the activation of the immune system and, thus, participate in antibacterial defense [1]. However, when ROS formation is unbalanced in proportion to protective antioxidants, the excess ROS can cause toxic effects that damage all components of the cell including lipids, proteins, and DNA and ultimately lead to cell death. Antioxidants prevent oxidant formation or scavenge the ROS produced under conditions of oxidative stress by binding and inactivating them. Most antioxidants are electron donors and react with ROS, which are free radicals, to form innocuous end products, such as water.

The primary sources of oxidative injury include superoxide anion (·O²−) and hydrogen peroxide (H₂O₂), which undoubtedly play important roles; however, these species also produce highly reactive hydroxyl radicals (·OH) and peroxynitrite (ONOO−) through the Haber-Weiss or Fenton reactions [2, 3]. Oxidative stress resulting from an imbalance between pro-oxidant and antioxidant systems, has been implicated in many diseases including cardiovascular disease, cancer [4], chronic inflammatory disease [5], hypertension [6], ischemia/reperfusion injury [7], acute respiratory distress syndrome (ARDS) [8], and neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease [9, 10], as well as in aging [11]. Exogenous administration of antioxidants has been utilized as a therapeutic approach and there is evidence that antioxidants protect against oxidative stress and prevent the pathological processes of a wide range of diseases.

Medical gases are pharmaceutical gaseous molecules which offer solutions to medical needs. They include tradi-
Additional gases, like oxygen and nitrous oxide, as well as gases with recently discovered roles as biological messenger molecules including nitric oxide, carbon monoxide and hydrogen sulphide. In this article, we will review recent advances and current knowledge pertaining to antioxidant medical gases including the three gaseous signaling molecules (nitric oxide, carbon monoxide and hydrogen sulphide), as well as hydrogen, xenon and ozone. Additionally, we will discuss their clinical applications and therapeutic properties (Table 1). These gases may be toxic, hazardous or poisonous at a higher concentration, however; they are safe and potentially therapeutic at lower concentrations. Medical gases can be administered in a straightforward way simply by providing the gas for the patients to inhale using a ventilator circuit, facemask, or nasal cannula. While there are a variety of delivery systems presently in use and even more under development, the basic design and goal of each system is to provide safe gas delivery and precision gas analysis or monitoring. In addition to the development of safe devices for inhaled medical gas, potential clinical application may include a parenteral injectable or a drug containing a gas-releasing moiety. Medical gas therapy is a relatively unexplored field of medicine; however, a recent increase in publications in the medical gas field clearly indicates that there are significant opportunities for the use of medical gases as therapeutic tools [12, 13].

**Nitric Oxide (NO)**

Nitric oxide (NO) is a colorless and poisonous gas which is generated by automobile and thermal power plants and causes a serious air pollutant. NO concentration in unpolluted air is approximately 0.01 parts per million (ppm). NO, together with NO2, participates in damage of ozone layer by absorbing high frequency ultraviolet light from the sun. However, NO is an important signaling molecule in the

---

**Table 1. Antioxidant medical gas**

|                        | nitric oxide | carbon monoxide | hydrogen | hydrogen sulphide | xenon | ozone |
|------------------------|--------------|-----------------|----------|-------------------|-------|-------|
| **formula**            | NO           | CO              | H2       | H2S               | Xe    | O3    |
| **color, odor**        | colorless, a mild, sweet odor | colorless, odorless | colorless, odorless | colorless, smell like rotten egg | colorless, odorless | pale blue a sharp, cold, irritating odor |
| **receptors**          | heme proteins | heme proteins | unknown | KATP channels | N-methyl-D-aspartate (NMMDA) | not determined |
| **flammable**          | no           | no              | yes      | yes               | yes   | no    |
| **toxicity**           | yes          | yes             | no       | yes               | yes   | yes   |
| **produced in mammalian cells?** | Yes. From L-arginine by nitric oxide synthase (NOS), or reduction of nitrite | Yes. Through heme degradation by heme oxygenase | No | Yes. From L-cysteine by CBS and CBE | No | Yes. In the white blood cells and other biological systems |
| **application except medical use** | rare except medical use | industrial fuels | analytical chemistry | light emitting devise | bleaching substances |
| **effects for vessels** | vasodilation | vasodilation | unknown | vasodilation | no change | vasodilation |
| **anti-apoptotic effects** | yes | yes | yes | yes | yes | yes (preconditioning) |
| **anti-inflammatory effects** | yes | yes | yes | yes | yes | yes (preconditioning) |
| **therapeutic human use** | pulmonary hypertension, lung transplantation ARDS | not available | decompression sickness in divers, breath test for mal-absorption | not available | general anesthesia, medical imaging (133Xe) | cancers, chronic fatigue syndrome, infectious disease |
body of mammals and was named “Molecule of the Year” in 1992 [14]. Inhaled NO is a relatively new United States Food and Drug Administration (FDA) investigational drug and numerous facilities are involved in clinical trials utilizing NO.

In normoxic conditions, NO is synthesized endogenously from the amino acid, L-arginine, by nitric oxide synthase (NOS). NO is also generated by the reaction of near-physiological levels of nitrite with deoxyhemoglobin, a nitrite reductase, along the physiological oxygen gradient [15]. In hypoxic or acidicotic conditions, NO is generated by reduction of nitrate. Under these conditions of very low tissue pH and oxygen tension, nitrite may be reduced to NO by disproportionation (acid reduction) or by the enzymatic action of xanthine oxidoreductase (XOR) (Fig. 1) [16, 17]. The half life of NO is measured in seconds and NO is eliminated rapidly as nitrite and nitrate in urine. Nitrite is also considered to have a role as an endocrine pool of NO [18].

Blood vessel dilation is one of the most well-known effects of NO. NO stimulates soluble guanylate cyclase (sGC) and increases cGMP content in vascular smooth muscle cells, resulting in relaxation of vascular tone and vasodilation. Sildenafil (Viagra®), a selective inhibitor of phosphodiesterase type 5 (PDE5) in vascular smooth muscle, blocks the degradation of cGMP, leading to relaxation of blood vessels by increasing levels of cGMP. This action of sildenafil has been used for stimulation of erections primarily by enhancing signaling through the NO pathway [19]. People taking nitrate medications that are converted to NO in the body, such as nitroglycerin, are contraindicated for PDE5 inhibitor treatment due to the potential of overstimulating the NO-cGMP pathway. In addition to its vasorelaxative effect, NO has a complex spectrum of actions including the regulation of platelet activity and the preservation of the normal structure of the vessel wall. NO, produced by endothelial nitric oxide synthase (eNOS) in vascular endothelial cells, activates sGC and plays a key anti-inflammatory role by inhibiting P-selectin expression and leukocyte recruitment [20]. Thus, the actions of NO on blood vessels may increase tissue blood supply and abate the inflammatory response, leading to protection of the tissues from oxidative insults.

NO abates oxidative injury via several mechanisms. NO reacts with peroxy and oxy radicals generated during the process of lipid peroxidation. These peroxy and oxy radical adducts continue the chain reactions in lipid peroxidation, resulting in compromised cell membranes [21]. The reactions between NO and these ROS can terminate lipid peroxidation and protect tissues from ROS-induced injuries [22]. Through the Fenton reaction, hydrogen peroxide oxidizes iron (II) and in the process generates an extremely reactive intermediate (the hydroxyl radical) which then carries out oxidations of various substrates [H₂O₂ + Fe²⁺ → Fe³⁺ + OH⁻ + hydroxyl radical (·OH)]]. NO prevents hydroxyl radical formation by blocking the predominant iron catalyst in the Fenton reaction [2]. Furthermore, NO reacts with iron and forms an iron-nitrosyl complex, inhibiting iron’s catalytic functions in the Fenton reaction [23]. Treatment of rat hepatocytes with NO imparts resistance to H₂O₂-induced cell death by induction of the rate-limiting antioxidant enzyme, heme oxygenase (HO)-1 [24]. In bacteria, NO activates the redox-sensitive transcriptional regulator protein (OxyR), resulting in the subsequent expression of proteins protective against ROS [25]. In addition, NO prevents the induction of some ROS-induced genes during tissue injury such as early growth response-1 (Egr-1), which activates a number of adhesion molecules and accelerates oxidative tissue injuries [26]. Thus, multiple mechanisms underlie the antioxidant properties of NO.

Identification of the cytoprotective abilities of NO to mitigate oxidative injuries in many model systems led to numerous formal studies that examined the effect NO on human patients. Multiple single-center studies demonstrated the ability of inhaled NO to improve the outcome of patients.

![Fig. 1. Biological NO production in human body.](image-url)

NO is generated from L-arginine by inducible nitric oxide synthase (iNOS) and endothelial NOS (eNOS). Alternatively, NO is produced from diet-derived nitrates, which are reduced to nitrite by bacteria in the alimentary tract. At very low tissue pH and oxygen tension, nitrite may be reduced to NO by the enzymatic action of xanthine oxidoreductase (XOR). Also, physiological levels of nitrite are reduced to NO by reaction with deoxyhemoglobin, a nitrite reductase, in the along the physiological oxygen gradient.
with ARDS. NO inhalation was associated with a redistribution of blood flow to well-ventilated areas in the lungs and improved oxygen levels in the blood [27, 28]. On the other hand, several studies showed that NO had no effects on ARDS [27, 29]. Similarly, some studies advocate inhalation of NO as a method to prevent graft injury due to ischemia/reperfusion injury after human lung [30] and liver transplantation [31], while others have demonstrated detrimental or marginal effects [32–34]. Some of the adverse effects of NO may be due to the formation of peroxynitrite (ONOO$^-$), a powerful pro-oxidant capable of causing organ injuries, by reaction of NO with superoxide anion [35]. Thus, studies examining the delivery of NO in experimental and clinical studies have shown discrepant results. NO may be linked both to protective and toxic effects after oxidative insults, depending on NO levels, NO source, timing of NO administration and the environment, suggesting a narrow therapeutic window for NO administration in the treatment of oxidative injuries [36].

**Carbon Monoxide (CO)**

CO occurs in nature as a product of oxidation or combustion of organic matter. CO is an invisible, chemically inert, colorless and odorless gas and is commonly viewed as a poison. CO avidly binds to hemoglobin and forms carboxyhemoglobin (COHb) with an affinity 240 times higher than that of oxygen, resulting in interference with the oxygen-carrying capacity of the blood and consequent tissue hypoxia. COHb levels of 10–30% can cause headache, shortness of breath and dizziness, and higher levels (30–50%) produce deleterious toxicity, such as severe headache, vomiting, syncope and arrhythmia, possibly death [37]. Thus, CO is widely known to be toxic at high concentrations.

Similar to NO, the gaseous molecule CO is endogenously and physiologically generated in mammalian cells via the catabolism of heme in the rate-limiting step by heme oxygenase (HO) systems [38]. Catabolism of heme by HO-1 is highly induced in a variety of tissues in response to diverse stress-related conditions [39], and provides generalized endogenous cytoprotection [40]. The specific mechanisms by which HO-1 can mediate endogenous cytoprotective functions are not clear, but byproducts generated during the heme catabolism such as CO, iron and biliverdin, have been suggested as potential protective mediators [41, 42]. In fact, CO, generated by HO-1 or exogenously administered, has beneficial biological and physiological functions. Potent therapeutic efficacies of CO have been demonstrated using experimental models for many conditions, including paralytic ileus [43], hemorrhagic shock [44], hypoxic lung injury [45], and endotoxemia [46], supporting the new paradigm that, at low concentrations, CO functions as a signaling molecule that exerts significant cytoprotection.

Several possible mechanisms have been postulated to explain the antioxidant effects of CO. CO binds to the heme moiety of mitochondrial cytochrome c oxidase and substantially decreases mitochondria-derived ROS [47, 48]. Additionally, this inhibition of mitochondria-derived ROS can result in low level ROS generation and trigger adaptive responses and cell survival, a novel mechanism to explain redox signaling by CO [49-51]. The strong affinity of CO for the heme moiety of other heme-containing proteins (referred to collectively as heme proteins) may also account for the antioxidant effects afforded by CO. During hemorrhage, hemolysis, or ischemia/reperfusion injury, damaged heme proteins are prone to degrade and release heme, which is highly lipophilic and detrimental. Heme can directly induce tissue injury by rapidly promoting peroxidation of the lipid membranes of the cells [52, 53]. Furthermore, free heme derived from degraded heme proteins during cellular injury is implicated as the source of catalytic iron that would participate in the Fenton reaction, converting H$_2$O$_2$ to more reactive hydroxyl radicals and promoting severe tissue damage by propagating lipid peroxidation. CO may prevent the degradation of heme proteins by binding to the heme moiety.

Cytochrome P450s (CYP), a large group of heme proteins which are abundant in many organs, are prone to degradation and the release heme and iron and play a critical roles during organ injury by various insults (Fig. 2) [54–62]. Recently, our group demonstrated that CO in the organ preservation solution used during transplantation can bind to and stabilize renal CYP and prevent CYP degradation and detrimental heme/iron release in renal grafts. This resulted in potent protection from transplant-induced ischemia/reperfusion injury [63]. Syngenic orthotopic kidney transplantation (KTx) with 24 h cold ischemia in UW solution (Viaspan®, Du Pont, Wilmington, DE) was performed using inbred male LEW (RT.1) rats. The excised graft was flushed with and preserved in UW or CO-supplemented UW (CO content; 40.6 ± 1.6 μmol/L). The graft functions treated in UW with CO showed better renal functions and fewer inflammatory events. The grafts stored in control preservation solution exhibited a markedly decreased total CYP levels in rat kidney 3 h after reperfusion, indicating CYP degradation during ischemia/reperfusion injury [63]. In contrast, the grafts stored in UW with CO maintained CYP enzyme at the levels comparable to those seen in normal kidney [63]. These data indicate that _ex vivo_ organ-targeted CO delivery during cold storage prevents CYP breakdown during the ischemia/reperfusion process.

In addition to its oxidative abilities, described above, free heme activates vascular endothelial cells and upregulates adhesion molecules such as intercellular adhesion molecule
(ICAM)-1 and E-selectin. These heme-induced adhesive events cause massive cellular infiltration and increased vascular permeability, contributing to the pathogenesis of local inflammatory processes by induction of monocyte chemoattractant protein (MCP-1) and nuclear factor (NF)-kappaB [64]. To cope with the problems caused by high free heme concentrations, the body is equipped with various defense mechanisms, namely the HO system. CO treatment can induce HO-1 in cells to protect against injury [65–67]. Thus, a detrimental excess of heme can be immediately removed by HO-1 enzymatic activity, induced by CO. The adverse effects of inhaled CO are a major concern for clinical use. CO combines with hemoglobin, interferes with the oxygen-carrying capacity of the blood and leads to tissue hypoxia. Soluble forms of CO, such as CO-releasing molecules, may overcome this problem and allow clinical application [68, 69]. Currently, several human clinical trials are ongoing for various pathophysiologic disease states testing the therapeutic effects of inhaled CO administered at concentrations similar to those used in animal transplantation models [70, 71]. A recent study demonstrated that the application of CO to animals at low concentrations approximating cigarette-smoke exposure caused no apparent lung pathology [72]. However, Myer et al. failed to obtain similar anti-inflammatory effects of CO in a human endotoxemia model as were seen in small and large animal experiments [71]. These discrepancies may be attributed to species-specific differences in the affinity of CO for hemoglobin, or physiological differences such as respiratory rate and sensitivity to lipopolysaccharides (endotoxins) [73, 74].

**Hydrogen (H₂)**

Hydrogen (H₂) is the lightest and most abundant of chemical elements, constituting nearly 90% of the universe’s elemental mass. In contrast, earth’s atmosphere contains less that 1 ppm of hydrogen. In concentrations over 5%, hydrogen can form explosive mixtures with air, as typified by the 1937 Hindenberg Zeppelin disaster. Although hydrogen is known to be highly flammable and to violently react with oxidizing elements, it is noteworthy that hydrogen has no risk of explosion at concentrations less than 4.6% (Safety and Standard for hydrogen and hydrogen systems; National Aeronautics and Space Administration “NASA”, 1997). Hydrogen has wide applications in physics and engineering. As hydrogen is a highly potent energy source, the industrial use of hydrogen is expanding, such as the use of hydrogen fuel cells for zero-emission vehicles.

In fact, hydrogen is physiologically and continuously produced in our body during fermentation of non-digestible carbohydrates, primarily in the large intestine, by numerous strains of intestinal bacteria and is excreted as flatus, further metabolized by flora or exhaled as a natural component of abdominal gas [75, 76], the basis for the routinely-used hydrogen breath test for gastrointestinal transit [77, 78]. Increased excretion of hydrogen in the breath after carbohydrate ingestion is considered a consequence of bacterial fermentation in the colon [79, 80]. Hydrogen gas is routinely administered to divers as hydreliox, which contains 49% hydrogen [81].

Gharib et al. reported that animals maintained in a hydrogen-supplemented hyperbaric chamber were signifi-
A. Nakao et al. J. Clin. Biochem. Nutr. 6

Significantly protected from schistosomiasis-associated chronic liver injury [82]. Hydrogen treatment significantly increased antioxidant enzyme activity, decreased lipid peroxide levels and decreased circulating proinflammatory cytokine levels. Consistent with this first report showing the antioxidant effect of hydrogen, Ohsawa et al. demonstrated that inhaled hydrogen gas (~4%) has antioxidant and anti-apoptotic properties that can protect the brain against ischemia-induced injury and stroke by selectively neutralizing the detrimental ROS [83]. Hydrogen selectively reduces the levels of hydroxyl radicals (·OH) mainly generated through the Fenton reaction and peroxynitrite (ONOO−) in vitro (Fig. 3). This report also suggests that hydrogen easily crosses the brain-blood barrier and can be safely administered to human patients [81]. More recently, our group has shown that hydrogen treatment ameliorates transplant-induced intestinal injuries including mucosal erosion and mucosal barrier breakdown. Perioperative inhalation of 2% hydrogen mitigated intestinal dysmotility following transplantation and reduced upregulation of inflammatory mediators, such as chemokine (C-C motif) ligand 2 (CCL2), interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α. Hydrogen significantly diminished lipid peroxidation compared to air-treated grafts, as indicated by elevated levels of malondialdehyde, a lipid peroxidation product, in air-treated grafts demonstrating an antioxidant effect of hydrogen [84]. Thus, treatment with hydrogen has several potential advantages over current therapies used for ischemia/reperfusion or oxidative injury.

The positive results of our experiments with CO inhalation and hydrogen inhalation alone led us to conduct experiments toward potentially more potent therapeutic gas strategy combined CO and hydrogen. The rationale behind this approach was based on our unpublished data and on previous observations demonstrating several differences in the biological actions of CO and hydrogen, even though both ameliorate cardiac cold IRI [85, 86]. There is no chemical reaction between CO and hydrogen at room temperature, and the gases can be administered together safely. The combined effects of CO and hydrogen were evaluated using our established model of cold ischemia/reperfusion injury. In this model, syngeneic heart transplantation (HTx) is conducted from Lewis (RT1l) rats to Lewis rats with 18 h of cold ischemic time in Celsior® (Pasteur Merieux Serums et Vaccins, Lyon, France). HTx is performed into the abdomen by anastomosing the graft aorta and recipient infrarenal aorta and the graft pulmonary artery and recipient inferior vena cava in an end-to-side manner [86, 87]. Myocardial injury is evaluated by measurement of the ischemic area of the grafts as visualized by 2,3,5-triphenyltetrazolium chloride (TTC) staining 3 h after reperfusion. Normal naïve hearts had negligible infarct area. The infarct area was significantly reduced by dual-treatment with CO and hydrogen, while either CO or hydrogen alone did not significantly decrease the infarct area compared to untreated controls. (NL: normal naïve heart, HTx: heart transplant, n = 4–5 for each group, *p<0.05 vs HTx/air).

In this model, syngeneic heart transplantation (HTx) is conducted from Lewis (RT1l) rats to Lewis rats with 18 h of cold ischemic time in Celsior® (Pasteur Merieux Serums et Vaccins, Lyon, France). HTx is performed into the abdomen by anastomosing the graft aorta and recipient infrarenal aorta and the graft pulmonary artery and recipient inferior vena cava in an end-to-side manner [86, 87]. Myocardial injury is evaluated by measurement of the ischemic area of the grafts as visualized by 2,3,5-triphenyltetrazolium chloride (TTC) staining 3 h after reperfusion [87, 88]. Cold ischemia/reperfusion injury results in significant damage to the cardiomyocytes. However, when both donor and recipient were treated with mixed gas therapy with 250 ppm of CO, 2% hydrogen in balanced air, the ischemic area was significantly reduced, while either CO or hydrogen alone did not significantly decrease the infarct area compared to untreated controls (Fig. 4). These results suggested that dual gas therapy with CO and hydrogen may have more potent protective effects against cardiac cold ischemia/reperfusion injury compared to single treatment.

Fig. 3. Hydrogen scavenges hydroxyl radicals. Hydrogen selectively neutralize hydroxyl radicals generated by the Fenton reaction.

Fig. 4. Hydrogen inhalation reduced ischemic area following heart grafts with prolonged cold ischemia. The extent of gross structural damage to heart graft was evaluated by TTC staining 3 h after reperfusion. Normal naïve hearts had negligible infarct area. The infarct area was significantly reduced by dual-treatment with CO and hydrogen, while either CO or hydrogen alone did not significantly decrease the infarct area compared to untreated controls. (NL: normal naïve heart, HTx: heart transplant, n = 4–5 for each group, *p<0.05 vs HTx/air).
Hydrogen Sulphide (H₂S)

Hydrogen sulphide (H₂S) is a colorless, toxic and flammable gas. It is a naturally occurring gas found in volcanic gases and some well waters and is also responsible for the foul odor of rotten eggs and flatulence. Toxic effects of hydrogen sulphide in humans include eye irritation, shortness of breath, and chest tightness at concentrations <100 ppm [89, 90]. Exposure to hydrogen sulphide at >1000 ppm may cause severe adverse effects, ranging from loss of consciousness to fatality [91]. Measurement of the concentration of thiosulfate in blood and urine is useful for determining hydrogen sulphide poisoning [92].

Hydrogen sulphide is endogenously synthesized from L-cysteine, a product of food-derived methionine, by cystathiononeβ-synthase (CBS) and cystathione-γ-lyase (CSE) (Fig. 5). Methionine adenosyltransferase (MAT) converts methionine to homocysteine. CBS catalyses the homocysteine to cystathionine conversion. CSE, subsequently, converts cystathionine to L-cysteine. L-cysteine is further metabolized to hydrogen sulphide by CBS and CSE [93, 94]. Hydrogen sulphide is produced normally in vertebrates, and is believed to help regulate body temperature and metabolic activity at physiological concentrations [95, 96]. Also, hydrogen sulphide exerts physiological effects in the cardiovascular system of vertebrates, possibly through modulation of K⁺-ATP channel opening or as a cellular messenger molecule involved vascular flow regulation [97, 98]. Recent studies have shown that hydrogen sulphide is a physiologic gaseous signaling molecule, as are NO and CO [12].

Administration of hydrogen sulphide produced a “suspended animation-like” metabolic status with hypothermia and reduced oxygen demand in pigs (who received it intravenously) [99] and mice (who received hydrogen sulphide via inhalation) [100, 101], thus protecting from lethal hypoxia. This hypometabolic state, which resembles hibernation, induced by hydrogen sulphide may contribute to tolerance against oxidative stress.

Some of the antioxidant effects of hydrogen sulphide can be explained by its effects on cytochrome c oxidase and mitochondrial functions, while its effects on gene expression may be related to actions on the the NFkB and extracellular signal-regulated kinase (ERK) pathways [102]. Cardiac protection from oxidative injury is, at least in part, due to the ability of hydrogen sulphide to activate myocardial Kₐ₅P channels, although this is still being elucidated [103]. Whiteman et al. showed that hydrogen sulphide has the potential to act as an antioxidant inhibitor of peroxynitrite-mediated processes via activation of N-methyl-D-aspartate (NMDA) receptors [104]. Kimura et al. revealed that hydrogen sulphide can shield cultured neurons from oxidative damage by increasing levels of glutathione, an antioxidant enzyme [105]. Similarly, hydrogen sulphide can induce upregulation of HO-1, anti-inflammatory and cytoprotective genes [102, 106]. Hydrogen sulphide also inhibits myeloperoxidase and destroys H₂O₂ [107] and can reduce ischemia/reperfusion-induced apoptosis via reduction of cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) [108]. Thus, multiple mechanisms may be involved in the antioxidant properties of hydrogen sulphide.

Xenon

Xenon is a noble gas considered chemically inert and unable to form compounds with other molecules. Xenon is a trace gas in Earth’s atmosphere, occurring at <0.001 ppm and is also found in gases emitted from some mineral springs. Xenon is not a “greenhouse gas” and, in fact, is viewed as enviromentally friendly gas [109].

Xenon possesses anesthetic properties in animals and humans [109–111]. Since Cullen first used xenon on human patients in 1951, xenon has been successfully used in a number of surgical operations [110]. Although the cost of xenon has been too high to be used routinely in surgical practice, xenon anesthesia systems are still being proposed and designed for certain cases of patients, as xenon has several advantages including greater circulatory stability,
lower analgesic consumption, lower adrenaline levels and better regional perfusion of individual organs [109, 112]. Xenon readily crosses the blood-brain barrier and has low blood/gas solubility, which is advantageous for rapid inflow and washout [113]. Human patients anaesthetized with xenon show good cardiovascular stability and satisfactory sedation [117]. Also, xenon inhalation had no measurable effects on mesenteric vascular resistance in the propofol-sedated pig [114].

In addition to its anesthetic properties, xenon has protective effects against cerebral ischemia [115]. Decreased blood flow to the brain leads to neuronal death through necrotic and apoptotic mechanisms, which are largely dependent on the activation of the NMDA receptor [116]. Since xenon effectively inhibits the NMDA receptor, the neuroprotective effects of xenon may be at least partially due to this inhibition [115, 117–119]. Similarly, Abraini et al. showed that xenon reduced ischemia-induced neuronal death induced by occlusion of the middle cerebral artery in rodents, and decreased NMDA-induced Ca\(^{2+}\) influx, a critical event involved in excitotoxicity, in neuronal cell cultures [120]. Also, xenon has inhibitory effects on the Ca\(^{2+}\)-ATPase pump and interferes with the Ca\(^{2+}\) intracellular signaling pathway, which might also be involved in the prevention of ischemic injury [121].

There is evidence suggesting that brief exposure to xenon prevents myocardial ischemia/reperfusion injury [122]. Although exact mechanism involved in prevention of ischemia-induced myocardial injury are still not fully elucidated, xenon significantly activates protein kinase C (PKC)-epsilon and leads to phosphorylation of p38 mitogen-activated protein kinase (MAPK). This signaling may represent a central molecular mechanism for xenon’s protective effects [122, 123]. Interestingly, other noble gases, such as helium, neon and argon, have also been shown to convey protection against cardiac ischemia/reperfusion injury [124].

Ozone

Ozone is a triatomic molecule, consisting of three oxygen atoms. Ozone is a pale blue gas with a sharp, cold, irritating odor and is produced naturally by electrical discharges following thunderstorms or ultraviolet (UV) rays emitted from the sun. Ozone is present in low concentrations throughout the Earth’s atmosphere; however, an ozone layer exists between 10 km and 50 km above from the surface of the earth and plays a very important role filtering UV rays which is critical for the maintenance of biological balance in the biosphere [125, 126]. Ozone gas has a high oxidation potential and is used in as an antimicrobial agent against bacteria, viruses, fungi, and protozoa. In particular, supplementation of ozone into spas and hot tubs can reduce the amount of chlorine or bromine required to maintain cleanliness by reactivating chlorine and bromine to their free states. Also, ozone is also widely used in treatment of water in aquariums and fish ponds to minimize bacterial growth, control parasites, and eliminate transmission of some diseases. Ozone inhalation (0.1 to 1 ppm) can be toxic to the pulmonary system and cause upper respiratory irritation, rhinitis, headache, and occasionally nausea and vomiting. Ozone, administered by rectal insufflation, prior to ischemia/reperfusion injury, prevents the damage induced by ROS and attenuate renal and hepatic ischemia/reperfusion injury [127–129]. It is postulated that ozone could prepare the host to face physiopathological events mediated by ROS, through NO-related mechanisms by modulating increases in eNOS and iNOS expression [127, 130, 131]. In addition, ozone has vasodilative effects without affecting any other cardiopulmonary parameters [132]. Al-Dalain et al. demonstrated that the ozone treatment improved glycemic control and prevented oxidative stress in diabetic rats. This study suggested that repeated administration of ozone in non-toxic doses might play a role in the control of diabetes and its complications [133]. Medical applications of blood ozonation via extracorporeal blood oxygenation and ozonation (EBOO) was found to be safe and effective in treating peripheral artery disease in clinical trials [126, 134–136].

Conclusion

As highlighted above, the ability of medical gases to ameliorate oxidative stress plays important roles at the chemical, cellular and physiological levels. Although some medical gases may cause serious adverse effects, there are still many possible applications of these gases as therapeutic tools for various diseases if the concentrations are tightly controlled. The future of medical gas therapy must focus on the establishment of safe and well-defined administration parameters and on randomized controlled trials to determine the precise indications and guidelines for the use of medical gases in the treatment of various pathologies.

Acknowledgement

We thank Shannon L. Wyszomierski PhD, Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center for excellent scientific editorial services. We also wish to thank Dr Noriko Murase, Dr Junichi Kohmoto and Dr David R Kaczorowski for valuable supports.

Abbreviations

ARDS, acute respiratory distress syndrome; CBS, cystathionine\(\beta\)-synthase; cGMP, cyclic guanosine mono-
References

[1] Reth, M.: Hydrogen peroxide as second messenger in lymphocyte activation. *Nat. Immunol.*, 3, 1129–1134, 2002.

[2] Menasche, P., Grousset, C., Gauduel, Y., Mouas, C., and Piwnica, A.: Prevention of hydroxyl radical formation: a critical concept for improving cardioplegia. Protective effects of deferoxamine. *Circulation*, 76, 180–185, 1987.

[3] Bernard, M., Menasche, P., Pietri, S., Grousset, C., Piwnica, A., and Cozzone, P.J.: Cardioplegic arrest superimposed on evolving myocardial ischemia. Improved recovery after inhibition of hydroxyl radical generation by peroxidase or deferoxamine. A 31P nuclear resonance study. *Circulation*, 78, 164–172, 1988.

[4] Cerutti, P.A. and Trump, B.F.: Inflammation and oxidative stress in carcinogenesis. *Cancer Cells*, 3, 1–7, 1991.

[5] Ha, H., Park, J., Kim, Y.S., and Endou, H.: Oxidative stress and chronic allograft nephropathy. *Yonsei Med. J.*, 45, 1049–1052, 2004.

[6] Watson, T., Goon, P.K., and Lip, G.Y.: Endothelial Progenitor Cells, Endothelial Dysfunction, Inflammation, and Oxidative Stress in Hypertension. *Antioxid. Redox Signal.*, 10, 1079–1788, 2008.

[7] Nakao, A., Kaczorowski, D.J., Sugimoto, R., Billiar, T.R., and McCurry, K.R.: Application of heme oxygenase-1, carbon monoxide and biliverdin for the prevention of intestinal ischemia/reperfusion injury. *J. Clin. Biochem. Nutr.*, 42, 78–88, 2008.

[8] Tasaka, S., Amaya, F., Hashimoto, S., and Ishizaka, A.: Roles of oxidants and redox signaling in the pathogenesis of acute respiratory distress syndrome. *Antioxid. Redox Signal.*, 10, 739–753, 2008.

[9] Nunomura, A., Moreira, P.I., Takeda, A., Smith, M.A., and Perry, G.: Oxidative RNA damage and neurodegeneration. *Curr. Med. Chem.*, 14, 2968–2975, 2007.

[10] Loh, K.P., Huang, S.H., De Silva, R., Tan, B.K., and Zhu, Y.Z.: Oxidative stress: apoptosis in neuronal injury. *Curr. Alzheimer Res.*, 3, 327–337, 2006.

[11] Wei, Y.H., Lu, C.Y., Wei, C.Y., Ma, Y.S., and Lee, H.C.: Oxidative stress in human aging and mitochondrial disease-consequences of defective mitochondrial respiration and impaired antioxidant enzyme system. *Chin. J. Physiol.*, 44, 1–11, 2001.

[12] Szabo, C.: Hydrogen sulphide and its therapeutic potential. *Nat. Rev. Drug Discov.*, 6, 917–935, 2007.

[13] Dingley, J., Tooley, J., Porter, H., and Thoresen, M.: Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. *Stroke*, 37, 501–506, 2006.

[14] Culotta, E. and Koshland, D.E. Jr.: NO news is good news. *Science*, 258, 1862–1865, 1992.

[15] Cosby, K., Partovi, K.S., Crawford, J.H., Patel, R.P., Reiter, C.D., Martyr, S., Yang, B.K., Waclawiw, M.A., Zalos, G., Xu, X., Huang, K.T., Shields, H., Kim-Shapiro, D.B., Schechter, A.N., Cannon, R.O. 3rd, and Gladwin, M.T.: Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. *Nat. Med.*, 9, 1498–1505, 2003.

[16] Godber, B.L., Doel, J.J., Sapkota, G.P., Blake, D.R., Stevens, C.R., Eisenthal, R., and Harrison, R.: Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. *J. Biol. Chem.*, 275(11), 7757–7763, 2000.

[17] Webb, A., Bond, R., McLean, P., Uppal, R., Benjamin, N., and Ahluwalia, A.: Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. *Proc. Natl. Acad. Sci. U. S. A.*, 101, 13683–13688, 2004.

[18] Lundberg, J.O., Weitzberg, E., and Gladwin, M.T.: The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. *Nat. Rev. Drug Discov.*, 7, 156–167, 2008.

[19] Cartledge, J., Minhas, S., and Eardley, I.: The role of nitric oxide in penile erection. *Expert Opin Pharmacother.*, 2, 95–107, 2001.

[20] Ahluwalia, A., Foster, P., Scotland, R.S., McLean, P.G., Mathur, A., Perretti, M., Moncada, S., and Hobbs, A.J.: Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. *Proc. Natl. Acad. Sci. U. S. A.*, 101, 1386–13891, 2004.

[21] Halliwell, B.: Reactive oxygen species in living systems: source, biochemistry, and role in human disease. *Am. J. Med.*, 91, 14S–22S, 1991.

[22] Padmaja, S. and Huie, R.E.: The reaction of nitric oxide with organic peroxyl radicals. *Biochem. Biophys. Res. Commun.*, 195, 539–544, 1993.

[23] Wink, D.A., Miranda, K.M., Espey, M.G., Pluta, R.M., Hewett, S.J., Colton, C., Viteck, M., Feilisch, M., and Grisham, M.B.: Mechanisms of the antioxidant effects of nitric oxide. *Antioxid. Redox Signal.*, 3, 203–213, 2001.

[24] Kim, Y.M., Bergonia, H., and Lancaster, J.R., Jr.: Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. *FEBS Lett.*, 374, 228–232, 1995.

[25] Nunoshiba, T., deRojas-Walker, T., Wishnok, J.S., Tannenbaum, S.R., and Demple, B.: Activation by nitric oxide of an oxidative-stress response that defends Escherichia coli against activated macrophages. *Proc. Natl. Acad. Sci. U. S. A.*, 90, 9993–9997, 1993.

[26] Chiu, J.J., Wung, B.S., Hsieh, H.J., Lo, L.W., and Wang, D.L.: Nitric oxide regulates shear stress-induced early growth response-1. Expression via the extracellular signal-
regulated kinase pathway in endothelial cells. *Circ. Res.*, **85**, 238–246, 1999.

[27] Michael, J.R., Barton, R.G., Saffle, J.R., Mone, M., Markewitz, B.A., Hillier, K., Elstad, M.R., Campbell, E.J., Troyer, B.E., Whately, R.E., Liou, T.G., Samuelson, W.M., Carveth, H.J., Hinson, D.M., Morris, S.E., Davis, B.L., and Day, R.W.: Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. *Am. J. Respir. Crit. Care Med.*, **157**, 1372–1380, 1998.

[28] Troney, E., Collet, J.P., Shapiro, S., Guimond, J.G., Blair, L., Ducruet, T., Francoeur, M., Charbonneau, M., and Blaise, G.: Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. *Am. J. Respir. Crit. Care Med.*, **157**, 1483–1488, 1998.

[29] Adhikari, N.K., Burns, K.E., Friedrich, J.O., Granton, J.T., Cook, D.J., and Meade, M.O.: Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. *BMJ*, **334**, 779, 2007.

[30] Date, H., Triantafillou, A.N., Trulock, E.P., Pohl, M.S., Cooper, J.D., and Patterson, G.A.: Inhaled nitric oxide reduces human lung allograft dysfunction. *J. Thorac. Cardiovasc. Surg.*, **111**, 913–919, 1996.

[31] Lang, J.D. Jr, Teng, X., Chunmey, P., Crawford, J.H., Isbell, T.S., Shacko, B.K., Liu, Y., Jalha, N., Crowe, D.R., Smith, A.B., Cross, R.C., Fenrette, L., Kelley, E.E., Wilhite, D.W., Hall, C.R., Page, G.P., Fallon, M.B., Bynon, J.S., Eckhoff, D.E., and Patel, R.P.: Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. *J. Clin. Invest.*, **117**, 2583–2591, 2007.

[32] George, L., Xydas, S., Topkara, V.K., Ferdinando, C., Barnwell, E.C., Gableman, L., Sladen, R.N., Naka, Y., and Oz, M.C.: Clinical indication for use and outcomes after inhaled nitric oxide therapy. *Ann. Thorac. Surg.*, **82**, 2161–2169, 2006.

[33] Perrin, G., Roch, A., Michelet, P., Reynaud-Gaubert, M., Thomas, P., Doddoli, C., and Auffray, J.P.: Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content: a randomized clinical study. *Chest*, **129**, 1024–1030, 2006.

[34] Meade, M.O., Granton, J.T., Matte-Martyn, A., McRae, K., Weaver, B., Cripps, P., and Keshavjee, S.H.: A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. *Am. J. Respir. Crit. Care Med.*, **167**, 1483–1489, 2003.

[35] Szabo, C.: Multiple pathways of peroxynitrite cytotoxicity. *Toxicol. Lett.*, **140–141**, 105–112, 2003.

[36] Bolli, R.: Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. *J. Mol. Cell Cardiol.*, **33**, 1897–1918, 2001.

[37] von Burg, R.: Carbon monoxide. *J. Appl. Toxicol.*, **19**, 379–386, 1999.

[38] Tenhunen, R., Marver, H.S., and Schmid, R.: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. *Proc. Natl. Acad. Sci. U. S. A.*, **61**, 748–755, 1968.

[39] Dragun, D., Hoff, U., Park, J.K., Qun, Y., Schneider, W., Luft, F.C., and Haller, H.: Prolonged cold preservation augments vascular injury independent of renal transplant immunogenicity and function. *Kidney Int.*, **60**, 1173–1181, 2001.

[40] Fujita, T., Toda, K., Karimova, A., Yan, S.F., Naka, Y., Yet, S.F., and Pinksy, D.J.: Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. *Nat. Med.*, **7**, 598–604, 2001.

[41] Otterbein, L.E., Bach, F.H., Alam, J., Soares, M., Tao, L.H., Wysk, M., Davis, R.J., Flavell, R.A., and Choi, A.M.: Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. *Nat. Med.*, **6**, 422–428, 2000.

[42] Morse, D., Sethi, J., and Choi, A.M.: Carbon monoxide-dependent signaling. *Crit. Care Med.*, **30**, S12–17, 2002.

[43] Moore, B.A., Otterbein, L.E., Turler, A., Choi, A.M., and Bauer, A.J.: Inhaled carbon monoxide suppresses the development of postoperative ileus in the murine small intestine. *Gastroenterology*, **124**, 377–391, 2003.

[44] Pannen, B.H., Kohler, N., Hole, B., Bauer, M., Clemens, M.G., and Geiger, K.K.: Protective role of endogenous carbon monoxide in hepatic microcirculatory dysfunction after hemorrhagic shock in rats. *J. Clin. Invest.*, **102**, 1220–1228, 1998.

[45] Otterbein, L.E., Kolls, J.K., Mantell, L.L., Cook, J.L., Alam, J., and Choi, A.M.: Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. *J. Clin. Invest.*, **103**, 1047–1054, 1999.

[46] Kyokane, T., Norimizu, S., Tanai, H., Yamaguchi, T., Takeoka, S., Tsuchida, E., Naito, M., Nimura, Y., Ishimura, Y., and Suematsu, M.: Carbon monoxide from heme catabolism protects against hepatobiliary dysfunction in endotoxin-treated rat liver. *Gastroenterology*, **120**, 1227–1240, 2001.

[47] D’Amico, G., Lam, F., Hagen, T., and Moncada, S.: Inhibition of cellular respiration by endogenously produced carbon monoxide. *J. Cell Sci.*, **119**, 2291–2298, 2006.

[48] Alonso, J.R., Cardellach, F., Lopez, S., Casademont, J., and Miro, O.: Carbon monoxide specifically inhibits cytochrome c oxidase of human mitochondrial respiratory chain. *Pharmaco- col. Toxicol.*, **93**, 142–146, 2003.

[49] Bilban, M., Bach, F.H., Otterbein, L.S., Hedigeho, E., de Costa d’Avila, J., Esterbauer, H., Chin, B.Y., Usheva, A., Robson, S.C., Wagner, O., and Otterbein, L.E.: Carbon monoxide orchestrates a protective response through PPARgamma. *Immunity*, **24**, 601–610, 2006.

[50] Taille, C., El-Benna, J., Lanone, S., Boczkowski, J., and Motterlini, R.: Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle. *J. Biol. Chem.*, **280**, 25350–25360, 2005.

[51] Zuckerbraun, B.S., Chin, B.Y., Bilban, M., de Costa d’Avila, J., Rao, J., Billiar, T.R., and Otterbein, L.E.: Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species. *FASEB J.*, **21**, 1099–1106, 2007.

[52] Nath, K.A., Balla, J., Croatt, A.J., and Vercellotti, G.M.: A. Nakao et al.
Heme protein-mediated renal injury: a protective role for 21-aminosteroids in vitro and in vivo. Kidney Int., 47, 592–602, 1995.

[53] Kumar, S. and Bandyopadhyay, U.: Free heme toxicity and its detoxification systems in human. Toxicol. Lett., 175–188, 2005.

[54] Nakahira, K., Takahashi, T., Shimizu, H., Maeshima, K., Uehara, K., Fuji, H., Nakatsuka, H., Yokoyama, M., Akagi, R., and Morita, K.: Protective role of heme oxygenase-1 induction in carbon tetrachloride-induced hepatotoxicity. Biochem. Pharmacol., 66, 1091–1105, 2003.

[55] Toda, N., Takahashi, T., Mizobuchi, S., Fuji, H., Nakahira, K., Takahashi, T., Yamashita, M., Morita, K., Hirakawa, M., and Akagi, R.: Tin chloride pretreatment prevents renal injury in rats with ischemic acute renal failure. Crit. Care Med., 30, 1512–1522, 2002.

[56] Paller, M.S. and Jacob, H.S.: Cytochrome P-450 mediates its detoxification systems in human.

[57] Glende, E.A., Jr., Hruszkewycz, A.M., and Recknagel, R.O.: Critical role of lipid peroxidation in carbon tetrachloride-induced loss of aminopyrine demethylase, cytochrome P-450 and glucose 6-phosphatase. Biochem. Pharmacol., 25, 2163–2170, 1976.

[58] Maines, M.D., Mayer, R.D., Ewing, J.F., and McCoubrey, W.K. Jr.: Induction of kidney heme oxygenase-1 (HSP32) mRNA and protein by ischemia/reperfusion: possible role of heme as both promoter of tissue damage and regulator of HSP32. J. Pharmacol. Exp. Ther., 264, 457–262, 1993.

[59] Baliga, R., Zhang, Z., Baliga, M., and Shah, S.V.: Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int., 49, 362–369, 1996.

[60] Nakao, A., Faleo, G., Shimizu, H., Nakahira, K., Choi, A.M., McCurry, K.R., Takahashi, T., and Murase, N.: Ex vivo delivered carbon monoxide prevents cytochrome P450 degradation and ischemia/reperfusion injury of kidney grafts. Kidney Int., 74, 1009–1016, 2008.

[61] Wagener, F.A., Feldman, E., de Witte, T., and Abraham, N.G.: Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc. Soc. Exp. Biol. Med., 216, 456–463, 1997.

[62] Lee, B.S., Heo, J., Kim, Y.M., Shim, S.M., Pae, H.O., and Chung, H.T.: Carbon monoxide mediates heme oxygenase 1 induction via Nrfl2 activation in hepatoma cells. Biochem. Biophys. Res. Commun., 343, 965–972, 2006.

[63] Sawle, P., Foresti, R., Mann, B.E., Johnson, T.R., Green, C.J., and Motterlini, R.: Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. Br. J. Pharmacol., 145, 800–810, 2005.

[64] Hegazi, R.A., Rao, K.N., Mayle, A., Sepulveda, A.R., Otterbein, L.E., and Plevy, S.E.: Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J. Exp. Med., 202, 1703–1713, 2005.

[65] Motterlini, R., Mann, B.E., and Foresti, R.: Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin. Investig. Drugs, 14, 1305–1318, 2005.

[66] Nakao, A., Toyokawa, H., Tsung, A., Nalesnik, M.A., Stolz, D.B., Kohmoto, J., Ikeda, A., Tomiyama, K., Harada, T., Takahashi, T., Yang, F., Fink, M.P., Morita, K., Choi, A.M., and Murase, N.: Ex vivo application of carbon monoxide in university of wisconsin solution to prevent intestinal cold ischemia/reperfusion injury. Am. J. Transplant., 6, 2243–2255, 2006.

[67] Choi, A.M. and Dolinay, T.: “Therapeutic” carbon monoxide may be a reality soon. Am. J. Respir. Crit. Care. Med., 171, 1318–1319, 2005.

[68] Mayr, F.B., Spiel, A., Leitner, J., Marsik, C., Germann, P., Ullrich, R., Wagner, O., and Jilma, B.: Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am. J. Respir. Crit. Care Med., 171, 354–360, 2005.

[69] Sorhaug, S., Steinhams, S., Nilsen, O.G., and Waldum, H.L.: Chronic inhalation of carbon monoxide: effects on the respiratory and cardiovascular system at doses corresponding to tobacco smoking. Toxicology, 228, 280–290, 2006.

[70] Redl, H., Bahrami, S., Schlag, G., and Traber, D.L.: Clinical detection of LPS and animal models of endotoxemia. Immunobiology, 187, 330–345, 1993.

[71] Klimisch, H.J., Chevalier, H.J., Harke, H.P., and Dontenwill, W.: Uptake of carbon monoxide in blood of miniture pigs and other mammals. Toxicology, 3, 301–310, 1975.

[72] Christl, S.U., Murgatroyd, P.R., Gibson, G.R., and Cummings, J.H.: Production, metabolism, and excretion of hydrogen in the large intestine. Gastroenterology, 102, 1269–1277, 1992.

[73] Hammer, H.F.: Colonic hydrogen absorption: quantification of its effect on hydrogen accumulation caused by bacterial fermentation of carbohydrates. Gut, 34, 818–822, 1993.

[74] Schneider, A.R., Jepp, K., Murczynski, L., Biniek, U., and Stein, J.: The inulin hydrogen breath test accurately reflects oroacael transit time. Eur. J. Clin. Invest., 37, 802–807, 2007.

[75] Di Camillo, M., Marinaro, V., Argnani, F., Fuglietta, T., and Vernia, P.: Hydrogen breath test for diagnosis of lactose malabsorption: the importance of timing and the number of breath samples. Can. J. Gastroenterol., 20, 265–268, 2006.

[76] Levine, M.D. and Donaldson, R.M.: Use of respiratory hydrogen (H2) excretion to detect carbohydrate malabsorption. J. Lab. Clin. Med., 75, 937–945, 1970.

[77] Strocci, A., Corazza, G., Ellis, C.J., Gasbarrini, G., and Levine, M.D.: Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H2 criteria. Gastroenterology, 105, 1404–1410, 1993.
[81] Abraini, J.H., Gardette-Chauffour, M.C., Martinez, E., Rostain, J.C., and Lemaire, C.: Psychophysiologic reactions in humans during an open sea dive to 500 m with a hydrogen-helium-oxygen mixture. J. Appl. Physiol., 76, 1113–1118, 1994.

[82] Gharib, B., Hanna, S., Abdallahi, O.M., Lepidi, H., Gardette, B., and De Reggi, M.: Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. C. R. Acad. Sci. III, 324, 719–724, 2001.

[83] Ohsawa, I., Ishikawa, M., Takahashi, K., Watanabe, M., Nishimaki, K., Yamagata, K., Katsura, K., Katayama, Y., Asoh, S., and Ohta, S.: Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med., 13, 688–694, 2007.

[84] Buchholz, B.M., Kaczorowski, D.J., Sugimoto, R., Yang, R., Wang, Y., Billiar, T.R., McCurry, K.R., Bauer, A.J., and Nakao, A.: Hydrogen Inhalation Ameliorates Oxidative Stress in Transplantation Induced Intestinal Graft Injury. Am. J. Transplant., 8, 2015–2024, 2008.

[85] Akamatsu, Y., Haga, M., Tyagi, S., Yamashita, K., Graca-Souza, A.V., Ollinger, R., Czismadia, E., May, G.A., Iffediego, E., Otterbein, L.E., Bach, F.H., and Soares, M.P.: Heme oxygenase-1-derived carbon monoxide protects hearts from transplant associated ischemia reperfusion injury. FASEB J., 18, 771–772, 2004.

[86] Nakao, A., Neto, J.S., Kanno, S., Stolz, D.B., Kimura, Y., Liu, F., Bach, F.H., Billiar, T.R., Choi, A.M., Otterbein, L.E., and Murase, N.: Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am. J. Transplant., 5, 282–591, 2005.

[87] Nakao, A., Toyokawa, H., Abe, M., Kiyomoto, T., Nakahira, K., Choi, A.M., Nalesnik, M.A., Thomson, A.W., and Murase, N.: Biliverdin administration prevents the formation of intimal hyperplasia induced by vascular injury. Circulation, 112, 587–591, 2005.

[88] Beauchamp, R.O. Jr., Bus, J.S., Popp, J.A., Boreiko, C.J., and Andjelkovich, D.A.: A critical review of the literature on hydrogen sulfide toxicity. Crit. Rev. Toxicol., 13, 25–97, 1984.

[89] Reiffenstein, R.J., Hulbert, W.C., and Roth, S.H.: Toxicology of hydrogen sulfide. Annu. Rev. Pharmacol. Toxicol., 32, 109–134, 1992.

[90] Kage, S., Kashimura, S., Ikeda, H., Kudo, K., and Ikeda, N.: Fatal and nonfatal poisoning by hydrogen sulfide at an industrial waste site. J. Forensic. Sci., 47, 652–655, 2002.

[91] Kage, S., Nagata, T., and Kudo, K.: Determination of polysulphides in blood by gas chromatography and gas chromatography-mass spectrometry. J. Chromatogr., 564, 163–169, 1991.

[92] Wang, R.: Two’s company, three’s a crowd: can H2S be the third endogenous gaseous transmitter?. FASEB J., 16, 1792–1798, 2002.

[93] Fiorucci, S., Distretti, E., Cirino, G., and Wallace, J.L.: The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology, 131, 259–271, 2006.

[94] Kamoun, P.: Endogenous production of hydrogen sulfide in mammals. Amino. Acids., 26, 243–254, 2004.

[95] Lowicka, E. and Beltowski, J.: Hydrogen sulfide (H:S)—the third gas of interest for pharmacologists. Pharmacol. Rep., 59, 4–24, 2007.

[96] Wang, R.: The gasotransmitter role of hydrogen sulfide. Antioxid. Redox. Signal., 5, 493–501, 2003.

[97] Leslie, M.: Medicine. Nothing rotten about hydrogen sulfide’s medical promise. Science, 320, 1155–1157, 2008.

[98] Simon, F., Giudici, R., Duy, C.N., Schelzig, H., Oter, S., Groger, M., Wachter, U., Vogt, J., Speit, G., Szabo, C., Radermacher, P., and Calzia, E.: Hemodynamic and Metabolic Effects of Hydrogen Sulfide During Porcine Ischemia/Reperfusion Injury. Shock, In press, 2008.

[99] Blackstone, E., Morrison, M., and Roth, M.B.: H2S induces a suspended animation-like state in mice. Science, 308, 518, 2005.

[100] Blackstone, E. and Roth, M.B.: Suspended animation-like state protects mice from lethal hypoxia. Shock, 27, 370–372, 2007.

[101] Oh, G.S., Pae, H.O., Lee, B.S., Kim, B.N., Kim, J.M., Kim, H.R., Jeon, S.B., Jeon, W.K., Chae, H.J., and Chung, H.T.: Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic. Biol. Med., 41, 106–119, 2006.

[102] Johansen, D., Ytrehus, K., and Baxter, G.F.: Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury—Evidence for a role of K AT P channels. Basic Res. Cardiol., 101, 53–60, 2006.

[103] Whiteman, M., Armstrong, J.S., Chu, S.H., Jia-Ling, S., Wong, B.S., Cheung, N.S., Halliwell, B., and Moore, P.K.: The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite ‘scavenger’? J. Neurochem., 90, 765–768, 2004.

[104] Kimura, Y. and Kimura, H.: Hydrogen sulfide protects neurons from oxidative stress. FASEB J., 18, 1165–1167, 2004.

[105] Qingyou, Z., Junbao, D., Wei Jin, Z., Hui, Y., Chaoshu, T., and Chunyu, Z.: Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. Biochem. Biophys. Res. Commun., 317, 30–37, 2004.

[106] Laggnner, H., Muellner, M.K., Schreier, S., Sturm, B., Hermann, M., Exner, M., Gmeiner, B.M., and Kapiotis, S.: Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radic. Res., 41, 741–747, 2007.

[107] Sodha, N.R., Clements, R.T., Feng, J., Liu, Y., Bianchi, C., Horvath, E.M., Szabo, C., and Selkoe, D.J.: The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. Eur. J. Cardiothorac. Surg., 33, 906–913, 2008.
[109] Marx, T., Schmidt, M., Schirmer, U., and Reinelt, H.: Xenon anaesthesia. J. R. Soc. Med., 93, 513–517, 2000.
[110] Cullen, S.C. and Gross, E.G.: The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science, 113(2942), 580–582, 1951.
[111] Bedi, A., Murray, J.M., Dingley, J., Stevenson, M.A., and Fee, J.P.: Use of xenon as a sedative for patients receiving critical care. Crit. Care Med., 31, 2470–2477, 2003.
[112] Boomsma, F., Rupreht, J., Man in’t Veld, A.J., de Jong, F.H., Dzoljic, M., and Lachmann, B.: Haemodynamic and neurohumoral effects of xenon anaesthesia. A comparison with nitrous oxide. Anesthesia, 45(4), 273–278, 1990.
[113] Goto, T., Suwa, K., Uezono, S., Ichinose, F., Uchiyama, M., and Morita, S.: The blood-gas partition coefficient of xenon may be lower than generally accepted. Br. J. Anaesth., 80, 255–256, 1998.
[114] Bogdanski, R., Blobner, M., Fink, H., and Kochs, E.: Effects of xenon on mesenteric blood flow. Eur. J. Anaesthesiol., 20, 98–103, 2003.
[115] David, H.N., Haelewyn, B., Rouillon, C., Lecoq, M., Parsons, C.G., Danysz, W., Hesselink, M., Hartmann, S., Franks, J.J., Horn, J.L., Janicki, P.K., and Singh, G.: Effects of xenon on mesenteric blood flow. Eur. J. Anaesthesiol., 20, 98–103, 2003.
[116] Parson, C.G., Danyz, W., Hesselink, M., Hartmann, S., Lorenz, B., Wollenburg, C., and Quack, G: Modulation of NMDA receptors by glycine—introduction to some basic aspects and recent developments. Amino. Acids, 14, 207–216, 1998.
[117] Franks, J.J., Horn, J.L., Janicki, P.K., and Singh, G: Halothane, isoflurane, xenon, and nitrous oxide inhibit calcium ATPase pump activity in rat brain synaptic plasma membranes. Anesthesiology, 82, 108–117, 1995.
[118] Ma, D., Wilhelm, S., Maze, M., and Franks, N.P.: Neuroprotective and neurotoxic properties of the ‘inert’ gas, xenon. Br. J. Anaesth., 89, 739–746, 2002.
[119] Wilhelm, S., Ma, D., Maze, M., and Franks, N.P.: Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology, 96, 1485–1491, 2002.
[120] Abraini, J.H., David, H.N., and Lemaire, M.: Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Ann. N. Y. Acad. Sci., 1053, 289–300, 2005.
[121] Petzelt, C., Taschenberger, G., Schmehl, W., and Kox, W.J.: Xenon-induced inhibition of Ca2+-regulated transitions in the cell cycle of human endothelial cells. Pflugers. Arch., 437, 737–744, 1999.
[122] Preckel, B., Mullenheim, J., Moloschavij, A., Thamer, V., and Schlack, W.: Xenon administration during early reperfusion reduces infarct size after regional ischemia in the rabbit heart in vivo. Anesth. Analg., 91, 1327–1332, 2000.
[123] Weber, N.C., Toma, O., Wolter, J.I., Obal, D., Mullenheim, J., Preckel, B., and Schlack, W.: The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br. J. Pharmacol., 144, 123–132, 2005.

[124] Pagel, P.S., Krolikowski, J.G., Shim, Y.H., Venkataparam, S., Kersten, J.R., Weihrauch, D., Waltlter, D.C., and Pratt, P.F.: Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. Anesth. Analg., 105, 562–569, 2007.

[125] Nogales, C.G., Ferrari, P.H., Kantorovich, E.O., and Lage-Marcues, J.L.: Ozone therapy in medicine and dentistry. J. Contemp. Dent. Pract., 9, 75–84, 2008.

[126] Bocci, V.: Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators Inflamm., 13, 3–11, 2004.

[127] Chen, H., Xing, B., Liu, X., Zhan, B., Zhou, J., Zhu, H., and Chen, Z.: Ozone Oxidative Preconditioning Protects The Rat Kidney from Reperfusion Injury: The Role of Nitric Oxide. J. Surg. Res., in press, 2008.

[128] Ajamiieh, H., Merino, N., Candelario-Jalil, E., Menendez, S., Martinez-Sanchez, G., Re, L., Giuliani, A., and Leon, O.S.: Similar protective effect of ischemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury. Pharmacol. Res., 45, 333–339, 2002.

[129] Peralta, C., Leon, OS., Xaus, C., Prats, N., Jalil, EC., Planell, ES., Puig-Parellada, P., Gelpi, E., and Rosello-Catafau, J.: Protective effect of ozone treatment on the injury associated with hepatic ischemia-reperfusion: antioxidant-prooxidant balance. Free Radic. Res., 31, 191–196, 1999.

[130] Chen, H., Xing, B., Liu, X., Zhan, B., Zhou, J., Zhu, H., and Chen, Z.: Similarities between ozone oxidative preconditioning and ischemic preconditioning in renal ischemia/reperfusion injury. Arch. Med. Res., 39, 169–178, 2008.

[131] Chen, H., Xing, B., Liu, X., Zhan, B., Zhou, J., Zhu, H., and Chen, Z.: Ozone oxidative preconditioning inhibits inflammation and apoptosis in a rat model of renal ischemia/reperfusion injury. Eur. J. Pharmacol., 581, 306–314, 2008.

[132] Cheleolege, E.S., Gunther, R.A., Parsons, G.H., Colbert, S.R., Yousef, M.A., and Cross, C.E.: Acute ozone exposure increases bronchial blood flow in conscious sheep. Respir. Physiol., 82, 325–335, 1990.

[133] Al-Dalain, SM., Martinez, G., Candelario-Jalil, E., Menendez, S., Re, L., Giuliani, A., and Leon, OS.: Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Pharmacol. Res., 44, 391–396, 2001.

[134] Di Paolo, N., Bocci, V., Salvo, D.P., Palasciano, G., Biagioli, M., Meini, S., Galli, F., Ciari, I., Maccari, F., Cappelletti, F., Di Paolo, M., and Gaggiotti, E.: Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int. J. Artif. Organs., 28, 1039–1050, 2005.

[135] Di Paolo, N., Bocci, V., and Gaggiotti, E.: Ozone therapy. Int. J. Artif. Organs., 27, 168–175, 2004.

[136] Hernandez, F., Menendez, S., and Wong, R.: Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic. Biol. Med., 19, 115–119, 1995.